Stockwinners Market Radar for November 17, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:34 EST PaxMedica enters $20M equity investment agreement with Lincoln Park Capital - PaxMedica "announced that the company has entered into a purchase agreement and registration rights agreement for up to $20M with Lincoln Park Capital Fund, LLC. Under the terms and conditions of the Agreement, including effectiveness of a related registration statement, the company has the right, but not the obligation, to sell up to $20M of its shares of common stock to Lincoln Park over a 30-month period, subject to certain limitations. Any common stock that is sold to Lincoln Park will occur at a purchase price that is determined by prevailing market prices at the time of each sale with no upper limits to the price Lincoln Park may pay to purchase the common stock."

19:57 EST MultiPlan announces settlement of Delaware litigation - MultiPlan "announced that the company and certain current and former directors have entered into a settlement agreement to resolve a consolidated class action lawsuit that has been pending since March 2021. The settlement agreement expressly provides that the settlement does not constitute an admission by the defendants or a finding that the claims asserted had any merit, and the defendants continue to strongly deny the allegations of liability in the lawsuit. We expect that, upon approval by the court, the settlement will bring to an end all pending shareholder litigation against the Company and its directors. As previously disclosed in our SEC filings, a consolidated lawsuit captioned In Re MultiPlan Corp. Stockholders Litigation, C.A. No. 2021-0300-LWW has been proceeding in the Delaware Court of Chancery related to our October 8, 2020 business combination transaction. Defendants in the lawsuit include the former directors of Churchill Capital III Corp. as well as affiliates of Churchill III's sponsor. On November 17, 2022, the Company and the parties to the lawsuit entered into a settlement agreement to fully and finally resolve the lawsuit. In connection with the settlement, the Company and its insurers, have agreed to pay $33.75 million in exchange for a broad release of all claims related to the business combination and ownership of Churchill III stock and warrants from February 19, 2020 through October 8, 2020. The settlement is being paid pursuant to the Company's indemnification obligations and from available D&O insurance."

19:08 EST Amedisys confirms FY22 guidance - The company states: "In conjunction with leadership change, Amedisys confirms its full year guidance."

18:45 EST Palo Alto Networks CEO: We're taking a knife to our costs - In an interview on CNBC's Mad Money, Nikesh Arora said, "We always had plans to improve operating margins and we decided to accelerate them." The company is seeing signs of customers becoming more discerning and cautious, he added.

18:31 EST Four Corners Property announces $6.1M acquisition of Caliber Collision property - Four Corners Property Trus announces the acquisition of a Caliber Collision property for $6.1 million. The property is located in a strong retail corridor in Tennessee and is corporate operated under a net lease with approximately seven years of term remaining. The transaction was priced at a 6.7% cap rate including near term rent increases, credits received at closing, and exclusive of transaction costs or a 6.5% cap rate on rent as of the closing date.

18:10 EST MacroGenics earns $60M milestone with FDA approval of Teplizumab - MacroGenics reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics. Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement. "We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes." Under the agreement, Provention is obligated to pay MacroGenics contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to MacroGenics totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product. Based on MacroGenics' cash, cash equivalents and marketable securities balance as of September 30, 2022, plus projected and anticipated payments from partners, including timely receipt of the milestone payment from Provention, MacroGenics currently anticipates having a cash runway into late 2024.

17:56 EST Amazon.com exec sells $1.63M in common stock - In a regulatory filing, Amazon.com disclosed that its CEO of Worldwide Amazon Stores Douglas Herrington sold 15.8K shares of common stock on November 15th in a total transaction size of $1.63M.

17:48 EST Transocean acquires interest in ultra deepwater newbuild drillship - Transocean announced that one of its subsidiaries, together with Perestroika A.S. and funds managed by Lime Rock Management L.P., have formed a joint venture, Liquila Ventures Ltd. Liquila Ventures agreed with Daewoo Shipbuilding & Marine Engineering Co., to purchase Hull 3623, the ultra-deepwater newbuild drillship formerly known as West Aquila, for approximately $200M. Hull 3623 is a high specification, 1400 short-ton hookload ultra-deepwater drillship. This seventh-generation dual-activity drillship will have a large deck space, high load capacities, and will be dual-stack ready. Transocean has made a $15M noncontrolling investment in Liquila Ventures and maintains the exclusive right to market and manage the operations of the rig, which is expected to be delivered from DSME in the third quarter of 2023.

17:26 EST LifeSci Special Opportunities responds to announcement by Diffusion Pharma - LifeSci Special Opportunities Master Fund , the holder of 96,976 shares of common stock of Diffusion Pharmaceuticals, or approximately 4.8% of the Company's outstanding shares, issued a statement in response to the Company's misleading press release from November 14, 2022 and announced that it has nominated a slate of high quality director candidates for election at the Company's upcoming annual meeting to be held on December 30, 2022. LifeSci Special Opportunities Statement: "The Company's November 14, 2022 press release announcing that its board of directors has authorized a review and evaluation of potential strategic opportunities appears to have been deliberately timed in order to obscure prior attempts by third parties, including LifeSci Capital LLC, a commonly-owned affiliate of LifeSci Special Opportunities, acting on behalf of its clients, to engage the Board in discussions regarding potential strategic alternatives. The Company's press release endeavors to mislead stockholders regarding the facts as to LS Capital's efforts to constructively engage with the Company on possible pathways to unlock significant value for all of the Company's stockholders. Further, the announcement of the strategic review process appears to be a desperate and thinly veiled effort to distract stockholders and the market from the Company's failures, including the Board's and management's inability to develop their lead asset, Trans Sodium Crocetinate, and the catastrophic erosion of Diffusion's cash balances and stockholder value that has occurred under their leadership. We believe that stockholders will be able to see through these transparent attempts to deflect attention away from the Company's operational and share price underperformance, including the fact that the Company's share price has declined by approximately 78% from November 15, 2021 to November 11, 2022. We encourage stockholders to review our proxy materials as they become available, which will include additional information regarding our concerns with the Company."

17:19 EST General Dynamics awarded $146.73M Army contract - General Dynamics was awarded a $146.73M firm-fixed-price contract for flat-bottom hull Stryker vehicles. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of November 30, 2024. U.S. Army Contracting Command is the contracting activity.

17:14 EST AT&T sees elevated investment levels in 2022-2023, moderated spending in 2024 - CFO Pascal Desroches spoke today at the Morgan Stanley European Technology, Media & Telecom Conference where he provided an update to shareholders, stating: "The company has continued to add customers in its strategic focus areas of 5G and fiber as customer demand for connectivity services remains healthy. While the company continues to monitor the evolving economic backdrop, Desroches feels confident in the ongoing benefits of AT&T's simplified business model as a pure play connectivity provider. He believes AT&T's consistent go-to-market approach, along with an improved customer experience, continues to attract high-value customers. Desroches highlighted that the company is now lapping investments made over the past two years and realizing additional cost savings from its transformation initiatives to enhance its high-performing workforce, optimize and expand connectivity networks and improve distribution. Though the company remains vigilant around inflationary pressures impacting all elements of the economy, the benefits of its cost reduction measures are increasingly falling to the bottom line, as evidenced by AT&T's accelerating third quarter adjusted EBITDA growth. In addition, Desroches shared that he feels good about the resilient nature of AT&T's connectivity services, and that pricing actions are proving accretive and performing slightly better than anticipated. Desroches said that AT&T Fiber continues to deliver the best customer experience in the marketplace and he's pleased with the momentum in AT&T Fiber's ARPU and penetration rates for new fiber build. As AT&T expands to new markets, the company has seen AT&T Fiber first-year penetration rates about two times greater than historical norms. AT&T continues to expand its fiber footprint and has the ability to serve 18.5 million consumer locations and 3.0 million business locations in more than 100 metro areas with fiber. Desroches added that AT&T expects to achieve its target of 30 million-plus locations with fiber by the end of 2025. Additionally, AT&T is continuously exploring ways to expand where it can serve customers fiber, including outside of its traditional wireline service area. Desroches said that when AT&T Fiber is available, the company has also seen an uplift in subscriber penetration. Regardless of location, AT&T will target areas not currently widely served with fiber and that offer attractive returns. Fiber deployments also support AT&T's wireless business. Desroches shared that AT&T expects to invest at record levels this year to meet growing demand for core connectivity, while also meeting free cash flow guidance for the year in the $14 billion range and continuing to pay an attractive dividend. Desroches reiterated that AT&T expects elevated levels of capital investment in 2022 and 2023 with moderated investment beginning in 2024. The company remains focused on investing in building a sustainable and durable connectivity operation with improved cash generation and continues to be pleased with the return profile of its fiber and 5G investments. Desroches indicated that the company's long-term capital allocation priorities remain unchanged, 95% of the company's debt is fixed and that he continues to expect AT&T will use cash after dividends to reduce debt, with a goal of reducing net debt-to-adjusted EBITDA to the 2.5x range."

17:02 EST VIQ Solutions names Larry Taylor executive chairman - VIQ Solutions announced the appointment of the company's Chairman, Larry Taylor, as Executive Chairman. Additionally, the company announced the appointment of Tim Johnson as Senior Vice President of International. As both an executive and board member, Mr. Taylor's new role was created to work closely with the executive team and accelerate the company's delivery of increased profitability and enhanced cash flow generation in 2023. To achieve these goals, Taylor and executives will focus on completing the integration of recent Australian acquisitions, onboarding the company's large customer contracts, particularly in Australia, expanding the company's global delivery capability, and ensuring the organization is structured to maximize the value of its rapidly growing subscription based recurring revenue. These initiatives are critical to the company's success. There is no change to the composition of the Office of the CEO, including Sebastien Pare, CEO, Susan Sumner, President and COO, and Alexie Edwards, CFO; all of whom will report to Mr. Taylor. Mr. Taylor's broad financial and business experience will be brought to bear alongside the Office of the CEO and the Board of Directors.

16:57 EST Ampio's trading suspension withdrawn by NYSE American - Ampio received notification from NYSE American stating that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the company's common stock on the NYSE American. Following the fifteen-to-one reverse stock split of the company's common stock, which became effective November 9, the NYSE Regulation staff determined that the company's common stock was trading above the threshold of low selling price issues. As such, the Exchange has withdrawn its delisting determination and will be lifting the trading suspension of the company's common stock on the NYSE American. Ampio's continued listing on the Exchange will be predicated on it demonstrating compliance through a period of at least December 23, 2022. The company will update shareholders if and when it receives notification from the NYSE American that it has achieved compliance on this matter. Ampio's common stock will commence trading on the NYSE American on Tuesday, November 22, under the symbol "AMPE."

16:48 EST Oz Minerals to recommend BHP Group's revised acquisition proposal - BHP (BHP) has submitted a revised non-binding indicative proposal to the Board of OZ Minerals Limited (OZMLF) to acquire 100% of OZL by way of a scheme of arrangement for a cash price of A$28.25 per OZL share. This offer price represents the best and final price BHP is willing to offer under the Revised Proposal, in the absence of a competing proposal. The OZL Board has confirmed to BHP that it intends to unanimously recommend the Revised Proposal to OZL shareholders as being in the best interests of OZL shareholders in the absence of a superior proposal subject to the parties entering into a binding scheme implementation agreement following completion of BHP's confirmatory due diligence and an independent expert concluding that the Revised Proposal is in the best interests of OZL shareholders.

16:33 EST Granite selected for I-10 pavement rehabilitation project in Tucson - Granite announced that it has been awarded an approximately $15M rehabilitation contract by the Arizona Department of Transportation for pavement rehabilitation and bridge deck repair. The project will be funded by Federal Highway Administration and ADOT to improve an almost 10 mile stretch of Interstate 10 in Tucson, Arizona. The award is expected to be included in Granite's fourth quarter CAP. The pavement rehabilitation project is in Pima County, on I-10 within Tucson city limits, beginning at milepost 262.4 and extending east along I-10 to milepost 272. The scope of work includes the removal of existing asphaltic concrete friction course by milling and replacing with new asphalt-rubber concrete friction course, placing crack seal and fog coat on the shoulders, constructing guardrail, bridge deck repair and installing conduit, traffic signs, pavement markings, and highway lighting. Granite's Arizona Swan plant will provide approximately 29,000 tons of hot mix asphalt to the project, including 40 shifts of night paving which will increase daily plant production. "We have a longstanding relationship with ADOT, and this project will build on our current work with the organization," said Anthony Alfonso, Granite area manager. "The project team just completed two ADOT resurfacing projects in Q3 2022." The project is expected to begin December 2022 and to be completed August 2023.

16:29 EST HF Foods Group receives additional noncompliance letter from Nasdaq - HF Foods Group announced that the company received an additional notification letter from the Listing Qualifications Department of Nasdaq Stock Market on November 14 stating that the company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of all required periodic reports with the Securities and Exchange Commission. The Nasdaq notification letter was sent as a result of the company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30 and because the company remains delinquent in filing its Form 10-K for the year ended December 31, 2021, its Form 10-Q for the quarter ended March 31 and its Form 10-Q for the quarter ended June 30. The Nasdaq notification letter has no immediate effect on the listing or trading of the company's common stock on the Nasdaq Capital Market. On November 15, the Nasdaq Hearings Panel granted the company's request for an extended stay of delisting proceedings, to last until January 31, 2023. The company must provide an update to the Nasdaq Hearings Panel on the progress of its independent auditors' review and procedures by December 30. The company can regain compliance with Nasdaq's continued listing requirements at any time before January 31, 2023, by filing the Delinquent Reports with the SEC, as well as any subsequent periodic financial reports that may become due, and continuing to comply with Nasdaq's other continued listing requirements. The company intends to file with the SEC its Delinquent Reports and regain compliance with Nasdaq's continued listing requirements as soon as practicable. In connection with the preparation of the Delinquent Reports, the company's management is working diligently with its advisors to resolve complex technical and accounting issues. The issues relate to the previously disclosed independent investigation by the Special Investigation Committee of the Company's board of directors and the previously disclosed concurrent, non-public SEC investigation.

16:25 EST Williams-Sonoma falls 11% to $116.15 after Q3 results - Shares of Williams-Sonoma are down 11% or $14.28 afterhours after the company reported Q3 results and indicated that it would not reiterate or update its guidance through FY24. Previously, the company had backed its expectations of "long-term financial outlook of mid-to-high single digit annual net revenue growth, increasing revenues to $10B by F24".

16:23 EST Palo Alto Networks jumps 5% after Q1 results, FY23 guidance beat estimates - In after-hours trading, shares are up over 5% to $165.45.

16:21 EST Matthews sees FY23 adjusted EBITDA $215M-$235M - Bartolacci further stated: "As we look forward into fiscal 2023, we are currently projecting another year of consolidated sales growth. Order rates for our Industrial Technologies segment, particularly energy storage solutions, support our confidence in the continued growth of this segment next fiscal year. We also expect the recent acquisitions of Olbrich GmbH and R+S Automotive GmbH to significantly contribute to the segment's fiscal 2023 sales. Based on these expectations and considering the increasing interest across our entire energy storage solutions portfolio, it's possible annual sales for the Industrial Technologies segment could approach $500 million in fiscal 2023. For our Memorialization segment, we expect death rates to continue to normalize into fiscal 2023. We also expect the comparability challenges on unit volumes (primarily through the first three quarters of fiscal 2023) to be partially mitigated by recent pricing actions as well as growth in our cremation-related sales. Further, despite the ongoing challenges in our European markets, we are currently projecting improved performance for our SGK Brand Solutions segment resulting from their recent cost reduction initiatives. However, we expect currency rates to continue to impact year-over-year comparability. Accordingly, based on these considerations, we currently project consolidated adjusted EBITDA to be in the range of $215 million to $235 million for fiscal 2023. We remain cautious in our outlook as our results will be influenced by the timing of projects and current economic conditions, particularly in Europe and its impact on currency rates."

16:20 EST C.H. Robinson raises quarterly dividend to 61c per share from 55c - C.H. Robinson Worldwide announced that its Board of Directors declared an increase to its regular quarterly cash dividend to 61c per share from 55c per share, payable on January 3, 2023, to shareholders of record on December 2, 2022.

16:20 EST Rio Tinto says negotiations with Turquoise Hill special committee unsuccessful - The company states: "Rio Tinto (RIO) has carefully considered the concerns raised by minority shareholders of Turquoise Hill (TRQ) in relation to the dissent and dispute resolution provisions in the agreements it entered into with certain funds and other entities related to Pentwater Capital Management LP and SailingStone Capital Partners LLC that were previously announced on 1 November 2022. Rio Tinto in good faith has been negotiating with the Special Committee of Turquoise Hill on comparable provisions for other minority shareholders. However, notwithstanding the parties best efforts, those negotiations have been unsuccessful. Rio Tinto has now agreed to terminate the Agreements with the Named Securityholders. While Rio Tinto's proposed transaction to acquire, by way of a plan of arrangement, the approximately 49% of the issued and outstanding shares of Turquoise Hill that Rio Tinto does not own for C$43.00 per share in cash will proceed, there is no assurance that any of the Named Securityholders will continue to withhold their vote or whether any of them will vote for or against the Arrangement. All minority shareholders of Turquoise Hill will have access to the same dissent rights and statutory process through the Yukon Courts for Rio Tinto's Proposed Transaction as described in Turquoise Hill's circular dated 27 September 2022."

16:18 EST Rackspace Technology appoints Bobby Molu as CFO - Rackspace Technology (RXT) announced the appointment of Bobby Molu as CFO, effective January 16, 2023. Molu is filling the Rackspace Technology CFO role following the appointment of Amar Maletira to CEO in September. Molu joins Rackspace Technology from Mastercard (MA) where he was CFO of International Markets overseeing Europe, Asia Pacific, Middle East, Africa, Latin America and Caribbean markets.

16:16 EST AMD, Analog Devices resolve all ongoing patent litigations - AMD (AMD) and Analog Devices (ADI) announced that they have resolved all their ongoing patent litigations, based on mutually agreed upon terms. As part of this resolution, the two companies have committed to pursue technology collaborations to bring next generation solutions to their communications and data center customers.

16:11 EST Ardelyx director Mott acquires 567,000 common shares - In a regulatory filing, Ardelyx director David Mott disclosed the purchase of 567,000 common shares of the company on November 17 at a price of $1.7648 per share.

16:09 EST Centene signs agreement to sell Magellan Specialty Health to Evolent Health - Centene (CNC) has signed a definitive agreement to sell Magellan Specialty Health to Evolent Health (EVH). Centene expects to receive over $750M in the aggregate from the transaction. Centene acquired Magellan Specialty Health, also known as NIA, in January 2022 as part of its acquisition of Magellan Health. Magellan Specialty Health is a specialty benefit management organization that offers utilization management solutions to health plans, including radiology management, musculoskeletal management, physical medicine management, and genetic testing solutions. Upon closing, Centene and Evolent will launch a multi-year, national strategic partnership, in which Centene will continue and expand its relationship with Magellan Specialty Health. In addition, Centene will continue its ongoing expansion of Evolent's Oncology and End of Life Solutions, as well as evaluate other Evolent specialty solutions. Centene expects to receive approximately $600M in proceeds at closing, with at least $400M paid in cash and the remainder paid in Evolent common stock. In addition, Centene will receive up to $150M in cash and Evolent common stock in 2024 if certain performance metrics are achieved. The transaction is expected to close in the first half of 2023. Centene intends to use the majority of the net proceeds from the sale to repurchase stock and the balance to reduce debt. The transaction is expected to be neutral to Centene's Adjusted EPS in the 12-month period post-closing.

16:06 EST DigitalOcean names Matt Steinfort as new CFO - DigitalOcean "announced the appointment of Matt Steinfort as CFO beginning in early January 2023. Steinfort comes to DigitalOcean from Zayo, a global communications infrastructure platform with $2.6 billion in revenue in 2019, their last year as a public company. There he held the role of Chief Financial Officer and oversaw all financial operations, strategy and M&A beginning in 2017."

16:05 EST Aecom raises quarterly dividend by 20% to 18c per share - The dividend is payable on January 20, 2023 to stockholders of record as of the close of business on January 4, 2023.

16:04 EST Iveric bio announces FDA granted breakthrough designation for Zimura - IVERIC bio "announced that the FDA has granted Breakthrough Therapy designation for avacincaptad pegol - ACP, also known as Zimura - a novel investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to Age-Related Macular Degeneration. To date, ACP is the first and only investigational therapy to receive Breakthrough Therapy designation status for this indication, which was granted based on the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal clinical trials." Glenn P. Sblendorio, CEO, says: "We believe this Breakthrough designation reflects the fact that both GATHER1 and GATHER2 met their primary endpoint with a safety profile that meets the stringent criteria required. We are now focused on the execution of our full NDA submission and launch preparation, with the possibility of being first to market. We look forward to working collaboratively with the FDA to expedite the review timeline for avacincaptad pegol and to potentially bringing a new therapy to AMD patients impacted by GA."

16:03 EST Evolent Health to acquire NIA for $650M upfront consideration - Evolent Health (EVH) announced that it has entered into a definitive agreement to acquire NIA, the specialty benefit management organization owned by Centene (CNC) that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine, and genetics. NIA has revenues of approximately $250 million and stand-alone Adjusted EBITDA of approximately $50 million. Contracted service expansions from Centene combined with identified cost synergies are expected to increase run-rate Adjusted EBITDA to $85 million and be fully realized by the fourth quarter of 2024. Consideration for the acquisition includes $650 million at close plus additional contingent consideration of up to $150 million based on 2023 performance. The upfront consideration will be funded in part by $250 million in Evolent equity issued to the sellers at a price of $29.50, a 24% premium to the prior day's closing price, subject to lock-up provisions. Upon close, the NIA team and platform will be fully integrated into Evolent's value-based specialty care business, which includes New Century Health, Vital Decisions and IPG. In addition to the NIA acquisition, Evolent and Centene are expanding Centene's relationship with NIA and extending NIA's contracts with Centene through 2027. We believe these expansions will generate at least $20 million of Adjusted EBITDA by the fourth quarter of 2024. The transaction is subject to U.S. federal antitrust clearance and satisfaction of other customary closing conditions and is expected to close in the first half of 2023.

16:01 EST Chevron to acquire full ownership of Beyond6 CNG fueling network - Chevron U.S.A. Inc., a subsidiary of Chevron Corporation, announced it signed a definitive agreement to acquire full ownership of Beyond6, LLC and its network of 55 compressed natural gas stations across the United States from Chevron's current B6 co-owners, a subsidiary of Mercuria Energy Trading and B6 CEO Andrew West. "Chevron has seen strong demand for our RNG-to-CNG fuel offering from new and existing customers," said Andy Walz, Chevron's president of Americas Products. "Because of its carbon negative attribute and the ability of fleet operators to efficiently adapt vehicles to run on CNG, renewable natural gas can be a lower carbon solution for fleets seeking to reduce their lifecycle greenhouse gas emissions." Mercuria and Chevron will enter into a long-term supply relationship to deliver renewable natural gas to Chevron as part of the transaction. The transaction is subject to customary closing conditions.

15:16 EST Motorola Solutions raises quarterly dividend 11% to 88c per share - The next quarterly dividend will be payable in cash on Jan. 13, 2023, to shareholders of record at the close of business on Dec. 15, 2022.

15:06 EST GM sees EV adoption to approach 20% of U.S. industry sales in 2025 - General Motors told investors today at a meeting in New York City that in the next three years, "GM plans to move very aggressively toward EV leadership as EV adoption is expected to approach 20% of U.S. industry sales in 2025." The company stated in a press release in conjunction with the event: "GM will have multiple entries in pickup, SUV and luxury segments that represent about 70% of EV industry volume, including the Chevrolet Silverado EV, Blazer EV and Equinox EV, the Cadillac LYRIQ and the GMC Sierra EV; GM is launching a new digital retail platform with its U.S. dealer partners to enhance the shopping and purchase experience for EV customers and reduce costs to GM by an estimated $2,000 per vehicle; Five GM assembly plants in the U.S., Canada and Mexico will be building EVs; BrightDrop - GM's tech startup creating EVs, eCarts and software - is on track to reach $1 billion in revenue in 2023, as GM's CAMI plant in Ontario launches full production of the BrightDrop Zevo 600 delivery van next year, and scaling to a projected 50,000 units annually by 2025; GM's battery cell joint venture Ultium Cells will be operating plants in Ohio, Tennessee and Michigan by the end of 2024, making the company a leader in domestic cell production; a fourth U.S. cell plant is planned; GM has secured binding commitments for all the battery raw material it needs to deliver its 2025 capacity target; The company continues to secure its needs beyond 2025 with strategic supply agreements and direct investments in natural resource recovery, processing and recycling; GM's EV growth is supported by a highly profitable portfolio of internal combustion engine vehicles in North America, including market-leading pickups and SUVs, great quality, and consistently high scores for customer satisfaction with dealer sales and service." GM added: "In 2023, Chevrolet and GMC will press their advantage in the pickup market with the new 2024 Chevrolet Silverado HD and GMC Sierra HD, which will be available in the first half of 2023, as well as the new Chevrolet Colorado and GMC Canyon mid-size pickups."

14:06 EST Cartesian Growth shareholders approve business combination - Cartesian Growth, a publicly traded special purpose acquisition company, announced that in an extraordinary general meeting on November 17, its shareholders voted to approve its proposed business combination with Tiedemann Group and Alvarium Investments Limited. "Closing-related processes are underway; in the interest of merger-accounting simplicity, the closing will be held on or about January 3, 2023, after the end of the 2022 fiscal year," the company stated. Upon closing, the combined company will operate as Alvarium Tiedemann, or "AlTi," and its common stock and warrants are expected to be listed on NASDAQ under the ticker symbols "GLBL" and "GLBLW", respectively.

14:04 EST General Motors, Vale sign long-term nickel supply agreement - Vale Canada Limited, a subsidiary of Vale S.A. (VALE), and General Motors (GM), announced they have signed a term sheet for the long-term supply of battery grade nickel sulfate from Vale's proposed plant at Becancour, Quebec, Canada. The agreement secures for GM a supply of nickel sulfate from a U.S. free-trade partner to support its electric vehicle production needs in North America, the company said in a statement. Under terms of the agreement, Vale will supply battery grade nickel sulfate, equivalent to 25,000 metric tons per year of contained nickel, for use in GM's Ultium battery cathodes. The amount of contained nickel is sufficient to supply approximately 350,000 electric vehicles annually. Deliveries are targeted to commence in the second half of 2026. Vale and GM have also agreed to study collaborative ways to partner on advanced technology development and commercialization pathways to harvest recycled metals.

13:23 EST General Motors sees Brightdrop revenue at $1B annually by 2025, says Barra

13:22 EST General Motors CEO: 'ICE age is not over' amid shift to EVs

13:19 EST General Motors sees EVs being profitable in 2025, says CEO Barra - Comments taken from GM's Investor Day presentation.

12:50 EST KemPharm treatment of idiopathic hypersomnia granted FDA orphan designation - KemPharm's serdexmethylphenidate was granted FDA orphan designation as a treatment of idiopathic hypersomnia, according to a post to the agency's website. Reference Link

12:39 EST Northwest Biotherapeutics: Phase III trial met primary, secondary endpoint - Northwest Biotherapeutics reported that in its Phase III clinical trial both median survival and the "long tail" of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax-L. The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial, the company said in a statement. The trial results were reported today in a featured publication co-authored by more than 70 physicians from leading institutions across the U.S., Canada, U.K. and Germany, in the peer reviewed cancer journal JAMA Oncology, entitled "Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination with Extension of Survival Among Patients with Newly Diagnosed and Recurrent Glioblastoma". The company believes this is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma, and the first time in nearly 30 years that a Phase III trial of any type of treatment has shown such survival extension in recurrent glioblastoma.

12:00 EST Ormat Technologies falls -10.5% - Ormat Technologies is down -10.5%, or -$10.52 to $89.69.

12:00 EST BrightView falls -15.3% - BrightView is down -15.3%, or -$1.37 to $7.61.

12:00 EST Bath & Body Works rises 19.7% - Bath & Body Works is up 19.7%, or $6.13 to $37.26.

11:56 EST MDU Resources raises quarterly dividend to 22.25c per share - MDU Resources Group board of directors increased the company's quarterly common stock dividend to 22.25c per share, for an annualized dividend of 89c per share. This is the 32nd consecutive year that MDU Resources has increased its common stock dividend. The previous quarterly dividend was 21.75c per share. The company's quarterly dividend is payable Jan. 1, 2023, to stockholders of record Dec. 8, 2022

11:52 EST Pershing expects CP, KSU merger to create many growth opportunities

11:30 EST Chipotle still delivering robust margin expansion, says Pershing Square - Chipotle is still delivering robust margin expansion, even in the current environment, Pershing Square said.

11:18 EST Pershing Square 'happy' with execution in near-term at Universal Music Group

11:14 EST Ancora 'encouraged' by Hasbro's decision to initiate sales process for eOne - Ancora Holdings issued a statement regarding Hasbro's announcement that it has initiated a sale process for its eOne TV and film business. Fredrick DiSanto, Chairman and CEO of Ancora, and James Chadwick, President of Ancora Alternatives LLC, commented: "As outlined in our May letter to Hasbro's Board of Directors, divesting of eOne can improve the Company's long-term positioning by enabling it to deleverage, reduce operational complexity and reinvest in core segments and high-quality brands with strong growth trajectories. We are encouraged by Hasbro's decision to initiate a sale process that will be led by Chief Executive Officer Chris Cocks and supported by independent financial advisors. Our prior interaction with Mr. Cocks and other recent developments suggest to us that Hasbro is beginning to adopt investor feedback and pursue important strategic enhancements that can benefit shareholders, customers, employees and other partners over the long run."

11:01 EST Varian Medical announces first participant treated in GENESIS II trial - Varian announced that the first trial participant has been treated as part of GENESIS II microspheres for genicular artery embolization as treatment of mild to moderate knee osteoarthritis. GENESIS II is the largest randomized clinical trial of GAE to assess pain relief from this debilitating condition. GENESIS II is being conducted at the University Department of Radiology, Royal Berkshire NHS Foundation Trust, in Reading, UK. The trial targets mild to moderate osteoarthritis of the knee joint, a common condition and a leading cause of chronic disability. GAE is a minimally invasive procedure in which a small catheter is advanced into the genicular arteries, the small blood vessels that supply the knee joint and contribute to the inflammatory process. The Embozene microspheres are delivered through the catheter to reduce the blood supply to the areas of greatest inflammation in the knee with the goal of reducing pain. In the GENESIS II clinical trial, patients with knee osteoarthritis will either receive treatment with the Embozene microspheres or a sham control; they have the option to receive Embozene treatment later in the clinical trial. This clinical trial design allows more accurate assessment of pain relief from the new treatment.

10:22 EST Inotiv says employees of principal supplier of primates criminally charged - In a regulatory filing, Inotiv disclosed that on November 16, the company became aware that the U.S. Attorney's Office for the Southern District of Florida, or "USAO-SDFL," has criminally charged employees of the company's principal supplier of non-human primates, or "NHPs," along with two Cambodian officials, with conspiring to illegally import NHPs into the United States from December 2017 through January 2022 and in connection with seven specific imports between July 2018 and December 2021. "The company has previously disclosed that Orient BioResource Center, a company acquired by the company on January 27, 2022, and Envigo Global Services, a company acquired by the company on November 5, 2021, had received grand jury subpoenas from USAO-SDFL, requiring the production of documents and information related to their importation of NHPs into the United States. The company has been fully cooperating, and will continue to cooperate, with USAO-SDFL," the filing stated.

10:07 EST DLocal Ltd trading halted, volatility trading pause

10:04 EST U.S. Cellular appoints Kevin Lowell as EVP, CPO, head of communications - UScellular announced that effective Jan. 1, 2023, Kevin Lowell will be promoted to executive vice president, chief people officer and head of communications. He will replace Deirdre Drake, who announced her retirement after more than eight years at the company and 33 years as a human resources leader. Lowell currently serves as UScellular's senior vice president of information technology and has been with the company since 2003. UScellular also announced corresponding changes to its leadership team, effective Jan. 1, 2023: Robert Jakubek has been promoted to senior vice president of information technology and will be responsible for providing the foundational capabilities necessary for frontline associates to serve customers and for the delivery of products and services. He currently serves as vice president of engineering and network operations and has held various leadership roles since joining the company in 1993. Mike Dienhart has been named vice president of engineering and network operations and will be responsible for ensuring the superior quality of UScellular's network and leading the teams at the company's Network Operations Centers. He currently serves as vice president of supply chain and has been with the company since 2003. Renae Grob has been promoted to vice president of supply chain and will be responsible for all aspects of UScellular's supply chain operations, policies, strategic objectives and initiatives to help ensure a great experience for customers. She currently serves as senior director of channel supply chain and has been with the company since 2012.

10:00 EST Silvergate Capital falls -11.4% - Silvergate Capital is down -11.4%, or -$3.58 to $27.76.

10:00 EST Macy's rises 9.5% - Macy's is up 9.5%, or $1.88 to $21.59.

10:00 EST Bath & Body Works rises 24.8% - Bath & Body Works is up 24.8%, or $7.73 to $38.86.

09:50 EST Venus Acquisition Corp trading resumes

09:47 EST Silvergate Capital falls -10.4% - Silvergate Capital is down -10.4%, or -$3.26 to $28.08.

09:47 EST NL Industries rises 7.6% - NL Industries is up 7.6%, or 56c to $7.96.

09:47 EST Bath & Body Works rises 22.2% - Bath & Body Works is up 22.2%, or $6.91 to $38.04.

09:32 EST Emmaus Life Sciences receives Endari marketing authorization in Qatar - Emmaus Life Sciences announced that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar Ministry of Public Health granting marketing authorization for the commercial distribution and sale of Endari in the country. The company also announced that it received its first major purchase order from its distributor in the Kingdom of Saudi Arabia, where Endari is available on an early access basis only.

09:30 EST Venus Acquisition Corp trading halted, volatility trading pause

09:21 EST Terreno Realty executes early lease renewal in New York - Terreno Realty announced that it has executed an early lease renewal in Jamaica Queens, New York with a global freight forwarding provider. The early lease renewal of 63,000 square feet, which was to expire in December will now expire December 2027. Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles; Northern New Jersey/New York City; San Francisco Bay Area; Seattle; Miami; and Washington, D.C.

09:19 EST mPhase Technologies appoints Ben Matheny as chief service, mobilization officer - mPhase Technologies announced the addition of Ben Matheny as Chief Service and Mobilization Officer. This fills an essential technology role at a time when Pebble is launching an industry-first platform to reward and encourage consumer behavior that promotes sustainability. Most notably, he was one of the first employees at $17 billion software giant Palantir Technologies, where he served as Operations Manager for eight years during the company's early growth phase. Matheny's experience with helping to scale unicorn technology companies includes seven years as Senior Director of Operations at Addepar and most recently, as Head of Workplace at Aurora Innovation, Inc., a leader in self-driving technology that went public in 2021.

09:18 EST TriNet makes two key executive appointments - TriNet announced two new senior leadership roles designed to drive increased revenue growth and retention, improve operating strategies, and create a more comprehensive and integrated customer experience. Alex Warren, most recently TriNet's Senior Vice President of Customer Experience, has been named Chief Revenue Officer. Tom Rose, previously TriNet's Vice President of Customer Solutions, is now Senior Vice President of Customer Success and Operations. Both positions report directly to TriNet President and CEO, Burton Goldfield. Warren joined TriNet in 2017 and has more than 20 years of experience in the PEO industry. Rose has over 23 years with TriNet, where he began his tenure as an Account Executive.

09:17 EST Eris Oaknet, Cosmofix hold market launch meetings for Photocil products in India - Jupiter Wellness announced that Eris Oaknet Healthcare and Cosmofix Technovation had market launch meetings for Photocil products for the Indian market. The Eris Oaknet product is branded as "Photofirst" in India. Jupiter Wellness's scientific team presented at meetings in Mumbai last week hosted by executives from Eris Oaknet and Cosmofix to coincide with the product launch. The International Speaker Program in Mumbai, sponsored by Eris Oaknet, hosted over 100 dermatologists with speakers that included Professor Andy Goren, inventor of the technology, Professor Torello Lotti, University of Rome, a world-renowned expert in the treatment of vitiligo, and Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness, who presented the Company's pipeline of products. Local dermatology experts included Dr. Pravin Banodkar, Skin Crest Clinic, Mumbai, and Dr. Asheem Sharma, Chief Dermatologist, Skin Saga Center for Dermatology, West Mumbai. Earlier this month, the Company announced that Photofirst had been approved by the Central Drugs Standard Control Organisation, the "FDA of India", for sale in India. "The recent approval of Photofirst by CDSCO and now the launch meetings by Eris Oaknet and Cosmofix Technovation is great news for Jupiter Wellness and its shareholders," said Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness. "While in Mumbai I was able to meet with the marketing teams that are managing the product launch and was impressed with the marketing plan and depth of market research that had been conducted in preparation for a concerted market launch. Together with positive feedback on Photocil from leading dermatologists, I strongly believe that India will be an important and significant market for this product."

09:13 EST Hasbro initiates sale process for eOne TV and film business - Hasbro announced that, in connection with the company's strategic review process led by its new CEO, Chris Cocks, the board of directors has authorized a sale process for the part of its eOne TV and film business not directly supporting the company's Branded Entertainment strategy. Hasbro will maintain the capability to develop and produce animation, digital shorts, scripted TV and theatrical films for audiences related to core Hasbro IP. In support of its recently announced Blueprint 2.0 strategy, Hasbro plans to significantly increase strategic investment in key brands, with a focus on gaming, direct to consumer, Franchise Brands and licensing. The company plans to maintain significant development, production and financing capabilities to support its core brands across film, TV, animation and digital shorts. These projects will span Hasbro's beloved brands and will also include the development of new IP such as the recently announced Kiya and the Kimoja Heroes that is scheduled to premiere on Disney Junior and Disney+ in 2023. The company has retained J.P. Morgan and Centerview Partners to assist with the sale process.

09:12 EST Hub Group's David Yeager to retire as CEO, Phillip Yeager to succeed - Hub Group announced that, as part of a planned succession process, its Board of Directors approved several leadership changes that will become effective January 1, 2023. After serving as Chief Executive Officer of Hub Group for twenty-six years, David Yeager will retire as CEO while continuing in the role of Executive Chairman of Hub Group. In his new role, David Yeager will work closely with the new CEO to facilitate a seamless leadership transition and continue to drive the next phase of the Company's growth. Phillip Yeager, currently President and Chief Operating Officer of Hub Group, will succeed David Yeager as the Company's President and Chief Executive Officer. In his new role, Phil Yeager will join the Board of Directors of Hub Group effective January 1, 2023. Phil Yeager joined Hub Group in 2011 and has held leadership roles in several of the Company's operations. In addition, Hub announced several other leadership changes effective January 1, 2023. Brian Alexander will be promoted from Executive Vice President, Logistics to Chief Operating Officer. Brian Meents will be promoted from Executive Vice President, Account Management, Sales and Marketing to Chief Marketing Officer. Chris Hoffmeister will be promoted from Executive Vice President, Account Management to Chief Commercial Officer.

09:07 EST PTC to acquire ServiceMax for $1.46B in cash - PTC announced that it has signed a definitive agreement to acquire ServiceMax for approximately $1.46B in cash on a debt-free, cash-free basis from an entity majority owned by Silver Lake. ServiceMax is a recognized leader in cloud-native, product-centric field service management software. The acquisition is expected to strengthen PTC's closed-loop product lifecycle management offerings by extending the digital thread of product information into downstream enterprise asset management and FSM capabilities. Subject to the satisfaction of regulatory approval and other applicable closing conditions, the transaction is expected to close in early January 2023. The transaction is expected to be accretive to PTC's SaaS ARR and cash flow in FY23. ServiceMax is expected to contribute approximately $160M in ARR for PTC's Q2'23.

09:06 EST Atlis Motor Vehicle receives first orders for storage packs from HALEE Solar - Atlis Motor Vehicles announces it has received its first orders for residential energy storage packs from HALEE Solar, an Arizona-based socially responsible home energy system provider. "Continuing to develop the full capability of our Atlis ecosystem, we are proud to partner with a fellow Mesa, AZ based business to provide residential energy storage solutions to the community," stated Mark Hanchett, Atlis Motor Vehicles' Founder and CEO. "As a company based in the United States developing its own battery systems, we are uniquely suited to collaborate with socially responsible energy companies in the same way that we collaborate with EV OEMs - namely, by providing efficient and powerful energy solutions."

09:05 EST LivaNova receives 510 clearance for ECMO from FDA for LifeSPARC - LivaNova announced it received 510 clearance for extracorporeal membrane oxygenation, or ECMO, from the FDA for LifeSPARC, the company's next-generation Advanced Circulatory Support, or ACS, pump and controller system. LivaNova leveraged existing real-world evidence inclusive of data collected during the COVID-19 pandemic to receive this new indication.

09:04 EST Tetra Tech awarded $86M contract by U.S. Space Force - Tetra Tech announced that it has been awarded an $86M contract to provide information technology support to mission-critical systems for the U.S. Space Force, Space Systems Command. Under this 6.5-year contract, the Tetra Tech Federal IT Group will provide technology services for mission-critical facilities. Our technical experts will provide cutting-edge technology systems support and integrated digital solutions to ensure consistent, timely delivery of key information.

09:02 EST Grubhub, Rite Aid partner on nationwide delivery - Grubhub and Rite Aid announced that they've partnered to deliver thousands of Rite Aid's drugstore products right to customers' doorsteps. More than 2,000 locations in 16 states are available on the Grubhub Marketplace for delivery.

08:58 EST Comcast Business announces $3M investment to expand network in Virginia - Comcast Business announced a $3M investment to expand its smart, fast and reliable fiber-rich network in Charlottesville, Chesterfield, Fredericksburg, Reston, Sterling and Woodbridge, with plans to complete by the end of this year. This expansion will extend the company's high-performance Ethernet, Internet and advanced voice solutions, among other services, to more than 250 businesses and organizations in the areas. This investment comes on the heels of a $28M regionwide network expansion project, which was completed in June 2022 and connected nearly 7,000 additional businesses across areas in Delaware, Maryland, Virginia, West Virginia and Washington, D.C.

08:48 EST Apollo funds complete acquisition of Tenneco - Tenneco and Apollo announced that funds managed by Apollo affiliates have completed the previously announced acquisition of Tenneco. Veteran executive Jim Voss has been appointed CEO of Tenneco, effective immediately and as previously announced. Pursuant to the terms of the transaction, an affiliate of the Apollo Funds acquired all of the outstanding shares of Tenneco stock. Tenneco shareholders are entitled to receive $20.00 in cash for each share of Tenneco common stock owned. As a result of the transaction completion, Tenneco's common stock no longer trades on the New York Stock Exchange.

08:45 EST Twin Vee PowerCats says fastest growing U.S. catamaran brand in 2022 - Twin Vee PowerCats announced that it is the fastest growing power catamaran manufacturer year over year through June 2022, according to information collected by a market share data company dealing in the marine, recreational vehicle, powersports, trailer and manufactured housing industries. The data shows that Twin Vee's sales grew 12.5% from June 2021 - 2022 compared to the previous year, while four other major competitors saw single-digit growth or declining sales during the same period. The Company plans to expand its boat offering even further in the coming months. Twin Vee announced plans to introduce three new boat models named the STX for Sport Tournament last week. The STX model line will include a 24, 26, and 28-footer. Additionally, the Company is designing wholly new and unique boat models geared towards freshwater environments that they expect will help open new markets and increase Twin Vee's exposure

08:43 EST Agenus announces expanded data from Phase 1 study of botensilimab, balstilimab - Agenus announced expanded data from the Company's Phase 1 study of botensilimab and balstilimab in patients with advanced sarcoma. The data demonstrate that the combination offers strong durability and superior efficacy compared to what has been reported in separate trials for standard of care and other investigational therapies in sarcoma, including in sarcoma subtypes historically unresponsive to immunotherapy. The results will be presented tomorrow in an oral presentation at the Connective Tissue Oncology Society 2022 Annual Meeting in Vancouver, BC, Canada. Study Design and Highlights: A total of 13 evaluable patients with advanced sarcoma received either 1 or 2 mg/kg botensilimab every 6 weeks and 3 mg/kg balstilimab every 2 weeks. Objective responses: 46% overall response rate; Other PD-(L)1 + CTLA-4 combinations in a comparable patient population achieved only 12-16% response rates; 69% disease control rate. Durability: 67% objective responses ongoing at data cut-off; Median duration of response has not been reached. Survival: 12-month overall survival of 77%; Median overall survival has not been reached. Patient Sub-Populations: Objective response rate of 56% and disease control rate of 78% in 9 patients with angiosarcoma, including 3 of 4 patients with visceral angiosarcoma; Other PD-(L)1 + CTLA-4 combinations achieved only 20-25% response rates in patients with angiosarcoma, with no reported responses in 7 patients with visceral angiosarcoma; Responses observed in additional patients with sarcoma subtypes historically resistant to immunotherapy, including liposarcoma with leiomyosarcomatous differentiation. Tolerability: Botensilimab was well tolerated; no grade 4 or 5 treatment-related adverse events in this cohort. Safety profile similar to what has been previously reported in the Phase 1 botensilimab program, with no new immune-mediated safety signals observed

08:42 EST Scynexis comments on BARDA priority focus on investing in antifungal treatment - SCYNEXIS applauded action taken this week by the Biomedical Advanced Research and Development Authority, BARDA, to add to the areas of interest in its new Broad Agency Announcement, BAA, the development of antifungal Medical Countermeasures, MCM, to treat infections caused by drug-resistant fungal threats. For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections. "It is extremely exciting to see BARDA announce increased emphasis on fighting dangerous fungal pathogens," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "Ibrexafungerp, with its promising activity against multiple drug resistant and often-deadly fungal infections, has enormous potential to benefit patients with severe fungal disease and limited treatment options. As a leader in the antifungal area with multiple ongoing Phase 3 studies, SCYNEXIS is well positioned to answer BARDA's call to action, and we are pleased with our continued clinical progress as we remain committed to bringing our innovative, potent antifungal to market as a potential option for patients with difficult-to-treat fungal infections."

08:40 EST Surmodics reports 12-month data from SWING trial that met both primary endpoints - Surmodics announced that 12-month data from the SWING Trial, a first-in-human study of the company's Sundance Sirolimus drug-coated balloon, or DCB, was presented at the 49th Annual Symposium on Vascular and Endovascular Issues in New York City. The SWING Trial is a 35-subject prospective, multi-center, single-arm, feasibility study to evaluate the safety and performance of the Sundance Sirolimus DCB when used to treat occlusive disease of the infra-popliteal arteries. The Swing Trial enrolled subjects with stenotic or occluded lesions of the infrapopliteal arteries, a reference vessel diameter of 2 mm to 4 mm, and a total lesion length of less than or equal to230 mm for treatment with the Sundance Sirolimus DCB at eight sites in Australia, New Zealand, and/or Europe. They will be followed for 36 months post index procedure. The primary safety endpoint is defined as the number of subjects with a composite of freedom from Major Adverse Limb Event, or MALE, and perioperative death at 30 days following the index procedure. The primary efficacy endpoint is the rate of late lumen loss at six months, as assessed by quantitative vascular angiography. Both primary endpoints of the SWING Trial were achieved. Primary safety endpoint data showed no perioperative deaths or major amputations at 30 days, and just one major re-intervention was reported among the 35 trial subjects. The per protocol (PP) population reported an 8.0% rate of major adverse events (two clinically driven target limb revascularizations) at 6 months, with no additional adverse events reported for PP subjects in the 12-month data. Primary efficacy data show late lumen loss of 1.0 mm (+/-.79 mm) across 35 lesions at 6 months, indicating that the large luminal gain achieved immediately after the procedure was sustained post procedure. Target lesion primary patency rate, defined as freedom from target vessel occlusion or target lesion revascularization associated with deterioration or Rutherford Clinical Classification and/or increase in size of pre-existing wounds (or occurrence of new wounds), and lesion restenosis greater than50%, was 80% at 12 months in the PP population. The Rutherford Clinical Classification describes 7 categories of peripheral artery disease, including both the patient's clinical symptoms as well as objective findings, and is used to assess disease progression.

08:37 EST Tims China announces partnership with Alibaba's Freshippo - TH International Limited, the exclusive operator of Tim Hortons coffee shops in China, announced a two-year partnership with Freshippo, Alibaba Group's omnichannel retail chain for groceries and fresh goods. The partners will introduce co-branded coffee products for sale exclusively through Freshippo's online channels and physical stores. The initial co-branded coffee products, Velvet Cocoa Coffee and Chestnut Latte, will be available for sale in December. Freshippo will sell these products online through its official app and also offline through its over 300 brick-and-mortar stores located in 27 cities across China. Tims China and Freshippo will work together on research and development of the co-branded products, collaborating on product design, positioning, promotion, and pricing. Jiayu Zhao, Chief Merchandising Officer of Freshippo said, "Freshippo is committed to providing a one-stop grocery shopping experience for consumers in pursuit of living a fresher life. Our collaboration with Tims China will broaden the choices we offer consumers through providing more coffee products with new experiences and flavors."

08:35 EST ABVC BioPharma announces Phase II Vitargus study protocol approved by Thai FDA - ABVC BioPharma announced that the Vitargus Phase II Clinical Study Protocol has been approved by the Thailand Food and Drug Administration, FDA. Import licenses for the Vitargus medical device and SF6-Gas used as a comparator in the clinical study were issued to both TH001 and TH002 study sites in Thailand on November 2, 2022. Vitargus medical devices and SF6-Gas comparators will be shipped to Ramathibodi Hospital, Mahidol University located in Bangkok and Srinagarind Hospital, Khon Kaen University located in Khon Kaen Province in preparation for the Site Initiation Visit of the study planned to begin before the end of 2022. It is expected that a total of 20 or more patients undergoing vitreo-retinal surgery will be included in the study at the two selected sites. "We are pleased that our two Vitargus Phase II study sites in Thailand have received Import licenses from the Thai FDA and can begin the study before the end of this year," said Dr. Howard Doong, Chief Executive Officer of the Company. "We also note that our two Australian sites are soon expected to receive the green light from the Australian Therapeutic Goods Administration allowing us to proceed with the Australian study in early 2023." Dr. Doong further noted that "more study sites will be added in other countries later in 2023."

08:34 EST Edible Garden offers 'Poultry Mix' potted herbs at retailers - Edible Garden announced an integrated program with several of its major retail distribution partners to provide its Poultry Mix potted herbs in time for the holiday season.

08:33 EST Genasys adds four more California counties to Zonehaven evacuation contracts - Genasys announced multi-year Zonehaven software-as-a-service, SaaS, contracts with four additional California counties. "Our evacuation platform has been utilized during some of California's most difficult, dangerous, and life-threatening incidents over the last three years," said Richard Danforth, Chief Executive Officer, Genasys, Inc. "Zonehaven has quickly become a standard for evacuation management in the Golden State, having been used this year in more than 50 incidents ranging from wildfires and flooding to police actions and advisories. First responders, emergency management personnel, and more than 400,000 residents in Calaveras, Del Norte, Madera, and Shasta counties will now have access to Zonehaven evacuation resources under these contracts," continued Mr. Danforth. "Del Norte and Shasta join seven other heavily forested northern California counties covered by our software services that reduce evacuation time from hours to minutes." Danforth added, "These contracts advance our SaaS strategy and further expand our footprint in California. Our strategic investments to capture market share and improve profitability are gaining traction. Additional SaaS and hardware contracts are expected this year from other jurisdictions as we continue to expand our critical communications coverage throughout California and in other states."

08:32 EST Lightwave Logic announces issuance of U.S. patent - Lightwave Logic announced the issuance of a U.S. patent, the application of which was announced in June 2022, on a new invention that will enhance polymer modulator manufacturing in high-volume foundries when integrated with silicon photonics. The patent issuance - entitled "Hybrid electro-optic polymer modulator with silicon photonics" under patent number US 11,435,604 B2 - details a novel fabrication process that allows Lightwave Logic's proprietary polymers to be fabricated by silicon foundries in a high-volume manufacturing environment. The patent also details a more efficient process that allows for high yielding, high stability poling of polymers in a high-volume foundry manufacturing environment. The development of the Process Development Kit for this new optical hybrid optical modulator design is now in progress with Lightwave Logic's foundry partners.

08:31 EST Imunon announces strategic investment in Transomic Technologies - IMUNON announced a $375,000 investment in Transomic Technologies, a private company offering a comprehensive array of CRISPR, RNAi and gene expression tools and services. The Company has partnered with Transomic to utilize their custom vector construction services to continue to generate plasmids that are being developed and evaluated by IMUNON as part of their DNA vaccine program. As a condition of the investment, Michael Tardugno, IMUNON's executive chairman, will join the Transomic board of directors. "Given our continued progress with the PLACCINE DNA vaccine development program, we have made the strategic decision to continue to support Transomic Technologies with this investment," said Corinne Le Goff, president and chief executive officer of IMUNON. "We have been utilizing Transomic's custom vector construction and design services, and we are very pleased with the strength and flexibility of their platform."

08:24 EST SOBR Safe appoints Marius Karoy as director of commerical development - SOBR Safe announced the hiring of Marius Karoy, Director of Commercial Development. Prior to SOBRsafe, Marius served in various management roles with Instructional Technologies Inc., most recently as its CCO.

08:21 EST Surrey Bancorp board declares special cash dividend of 15c per share - The Board of Directors of Surrey Bancorp announced that it has declared a special cash dividend of 15c per share on the Company's common stock. The Board also declared a regular quarterly cash dividend of 10.5c per share on the Company's common stock. The cash dividends are payable on January 10, 2023, to shareholders of record as of the close of business on December 16, 2022.

08:19 EST Getaround announces executive team, board finance leadership - Getaround announced changes in its senior executive team and proposed Board of Directors to be in place at the closing of the InterPrivate II Acquisition Corp. business combination. Tom Alderman, Getaround's Vice President of Finance, has succeeded Laura Onopchenko as Chief Financial Officer. Onopchenko will remain with Getaround through November 30 to ensure an orderly transition, and remains a personal advisor to CEO Sam Zaid. Additionally, Ravi Narula has been nominated for election by InterPrivate II Acquisition Corp.'s shareholders to the post-business combination Board of Directors and, if elected, would serve as Audit Committee Chair. Alderman joined Getaround in 2017 and has approximately two decades of financial leadership with a focus on corporate finance and investment banking for leading companies in the broader technology ecosystem. Narula currently serves as Chief Financial Officer at FinancialForce. On May 11, 2022, Getaround announced its entry into a definitive business combination agreement with InterPrivate II Acquisition Corp. Upon the closing of the business combination, which is expected in the second half of 2022, the combined publicly traded company will be named Getaround.

08:17 EST Enovis announces the introduction of DynaNail Helix - Enovis announces the introduction of the DynaNail Helix, the latest addition to the DynaNail family and Enovis' expansive suite of foot and ankle products. DynaNail Helix is designed to achieve sustained dynamic compression for subtalar fusion with an innovative, anatomically friendly design and simple, screw-like insertion. "The flexible, pseudo elastic NiTiNOL element that DynaNail Helix offers is unlike typical static fixation devices that are available on the market. Not only does DynaNail Helix offer intraoperative manual compression, but it also allows for up to 4mm of post-operative compression in response to bone resorption or settling," said Gary Justak, President of Enovis Foot & Ankle. "This sustained compression is designed to give patients a better chance at healing faster, with fewer complications."

08:16 EST Ayala Pharmaceuticals presents poster on AL102 in desmoid tumors - Ayala Pharmaceuticals is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada. The ongoing RINGSIDE Pivotal Phase 2/3 clinical trial is evaluating the investigational new drug AL102, a potent, selective, oral gamma-secretase inhibitor. Positive interim results from the Phase 2 segment of this study were previously presented at ESMO 2022. Abstract Title: Initial Results of RINGSIDE, a Phase 2/3 Trial of AL102 for the Treatment of Desmoid Tumors: Desmoid tumor is an invasive proliferative disease of the connective tissue characterized by a variable and often unpredictable clinical course with no FDA-approved therapies. AL102 is a potent, orally available, selective gamma-secretase inhibitor being evaluated in the RINGSIDE Pivotal Phase 2/3 trial in desmoid tumors. The Phase 2 segment of the study enrolled 42 patients which were dosed in AL102 monotherapy cohorts of 1.2 mg, 2mg, or 4mg. The activity of AL102 was measured by the change in tumor volume and response as determined by blinded independent central review. At the data cut-off, 28 patients were evaluable for tumor volume and 29 were evaluable for RECIST with a scan at baseline and at least one additional scan at week 16. 12 patients had at least 2 MRI scans at data cut-off and were evaluable for efficacy. First partial response was observed at week 16 and three additional PRs were observed over the follow-up period: two at week 28 and one at week 40. 3 out of 4 PRs were observed at the 1.2 mg once-daily dose that was selected for the Phase 3 segment of the study. AL102 was generally well tolerated at all doses, with low rates of grade 3, and no grade 4 or 5 adverse events. Adverse events were consistent with mechanism of action of GSIs. Adverse events leading to discontinuation were all Grade 1 - 3 and occurred within 3 months of treatment initiation Adverse events related to ovarian dysfunction was observed in 22% of women of childbearing potential, and were all Grade 1 or 2. 1.2 mg once daily was selected as the dose to advance into the Phase 3 portion of RINGSIDE. Enrolment has begun in the Phase 3 segment of RINGSIDE, the randomized portion of the study Patients are also being enrolled in an open-label extension study.

08:15 EST Macy's saw unexpected slowdown in sales in October, continued into November - CEO Jeff Gennette says Macy's sales performance has improved over the last week.

08:13 EST Mesa Labs acquires Belyntic's peptide purification business - Mesa Laboratories announced the acquisition of substantially all of the assets and certain liabilities related to Belyntic GmbH's peptide purification business. The transaction price and near-term financial impact are not material to Mesa's ongoing operations. "The acquisition of Belyntic's peptide purification products provide Mesa with a natural complement to our peptide synthesis business by adding an advantaged consumables product line. The combination will enhance Mesa's focus on the biopharmaceutical market to support faster therapeutic development." said Gary Owens, President and Chief Executive Officer of Mesa. "Belyntic has developed a best-in-class solution for the parallel purification and modification of difficult peptides. Their Peptide Easy Clean ("PEC") Linker represents the first broadly applicable peptide purification kit that utilizes catch-and-release methodologies, drastically reducing the need for organic solvents, improving the ecological impact."

08:11 EST Jowell Global reports 32.5% GMV growth at 2022 Singles' Day Shopping Festival - Jowell Global announced strong results from its 12-day 2022 Singles' Day Shopping Festival. Over $24.5M was generated in gross merchandise volume during the festival, which represents an extraordinary 32.5% growth from last year.

08:10 EST Leaf Group appoints Ross Landsbaum as CFO - Leaf Group announces the appointment of Ross Landsbaum as CFO. Landsbaum will be responsible for overseeing financial management and planning for the company's diversified popular brands and media properties which include Well+Good, Hunker, Society6 and Saatchi Art. In his new role, he will be instrumental in driving the company's ambitious strategic objectives. He most recently served as CFO at Therabody, the wellness-tech producer of the ultra-popular Theragun massage gun and a broad range of wellness devices launched during his tenure. Landsbaum began his role on November 1 and reports to CEO Sean Moriarty.

08:08 EST Enphase Energy increases home energy system deployments in Belgium - Enphase Energy announced that installers of Enphase products in Belgium have seen growing deployments of Enphase Energy Systems powered by IQ Microinverters and IQ Batteries. "We're pleased to see more installers in Belgium choosing Enphase's products to meet the growing demand from homeowners across the country," said Dave Ranhoff, chief commercial officer at Enphase. "As Belgium is rapidly moving toward home electrification, we are committed to delivering industry-leading products and best-in-class customer service to this fast-growing and important solar market

08:07 EST BYND Cannasoft signs agreement for provision of software services - BYND Cannasoft Enterprises announced that it has signed an agreement for the provision of software services with one of Israel's leading air conditioning companies. Under the terms of the agreement, the Company will provide Benefit CRM Cloud-Based Software as a Service, SaaS, in special modules that include mobile applications and APIs. Family - Line Air Conditioner Company sells hundreds of thousands of air conditioners and is the fourth largest company in the production, marketing, and installation of air conditioners in Israel. BYND Cannasoft will design and manufacture modules dedicated to this sector with the intent of realizing the strategy and penetrating additional companies and deepening services in consumer goods companies. "The air conditioning industry generates billions of shekels in revenue every year in Israel and has enjoyed increasing growth in recent years," said Yftah Ben Yaackov, CEO and Director of BYND. "This agreement demonstrates the mutual commitment of BYND Cannasoft and Family-Line Air Conditioners to serving the needs of customers, as well as optimizing day-to-day functions."

08:06 EST VYNE Therapeutics doses first subjects in Phase 1a/b trial of VYN201 - VYNE Therapeutics announced that the first subjects have been dosed in a Phase 1a/b clinical trial evaluating VYN201 for the treatment of vitiligo. VYN201 is a locally administered, small molecule, pan-bromodomain and extra-terminal domain inhibitor that is being developed for the treatment of immuno-inflammatory diseases. The clinical trial is a first-in-human study designed to generate safety and pharmacokinetic data in healthy volunteers as well as provide early clinical proof-of-concept data in vitiligo patients. The Phase 1 study will be conducted in U.S.-based clinical centers. The Phase 1a portion of the study will evaluate single ascending/multiple ascending doses in up to 30 healthy volunteers with VYN201 applied topically once daily for up to two weeks. The primary objective of this portion of the study is to characterize the preliminary safety and pharmacokinetics of VYN201 and to determine the safe starting dose for the Phase 1b portion of the study. In the Phase 1b portion, up to 30 patients with a clinical diagnosis of non-segmental vitiligo will receive VYN201 once daily in up to three dose cohorts. Patients will receive treatment for an initial 8-week period based on currently available nonclinical safety data. The Company expects to extend the treatment period for up to an additional 12 weeks, subject to ongoing nonclinical safety assessments. The primary objective of the Phase 1b portion of the study will be to evaluate the safety and pharmacokinetics of VYN201. In addition, exploratory efficacy of VYN201 in non-segmental vitiligo patients will also be assessed. Clinical assessments will include safety, pharmacokinetics, local skin tolerance, efficacy, pharmacodynamic biomarkers and photography.

08:05 EST Incannex initiates BA/BE study to assess IHL-42X for OSA - Incannex Healthcare is pleased to announce that Incannex has initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1 2023. The BA/BE study will assess the pharmacokinetics and tolerability of the two active pharmaceutical ingredients in IHL-42X, dronabinol and acetazolamide, compared to the respective FDA reference listed drugs, as well as the effect of food on pharmacokinetics of the two APIs. The study will include 116 participants who will each complete four single dose treatment periods, being dosed with IHL-42X, dronabinol and acetazolamide under fasted conditions as well as IHL-42X under fed conditions. Blood samples will be collected over 48 hours and the concentrations of the APIs and their major metabolites in the samples will be analysed. The study will be conducted at CMAX Clinical Research in Adelaide, South Australia and managed by Novotech. The design of the BA/BE study is consistent with FDA recommendations for BA/BE and specific advice received by Incannex in the pre-IND meeting. The results of this study will form a critical component of a future new drug application, providing the necessary bridge to the reference listed drugs, thereby facilitating the use of historic safety data via the FDA505(b) regulatory pathway. In parallel with the BA/BE study, Incannex is preparing an IND application for submission to the FDA. An IND application is a comprehensive information document detailing the safety, efficacy, and quality of the IHL-42X drug product for the treatment of OSA and is precursory to conducting clinical trials at treatment sites in the United States. Once the IND is opened, it is continuously updated with research and development results for the purpose of ongoing assessment by the FDA. Incannex aims to submit the IND application in Q1 2023, followed shortly by the commencement of pivotal, multi-site, Phase 2/3 clinical trials investigating the effects of IHL-42X in patients with OSA. The trials will assess the safety and efficacy of IHL-42X at the best performing two doses from the proof-of-concept clinical trial, in patients with OSA over a 12-month treatment period. Participants will receive one of IHL-42X, dronabinol, acetazolamide or placebo for the entirety of the study. All participants will complete daily surveys on their sleep quality, attend monthly clinic visits to assess functional outcomes of sleep, cognitive function and other measures of safety and efficacy. Every 3 months, overnight polysomnography will be conducted to determine the effect of treatment on the patients' AHI. All drug treatments will be compared to placebo. In preparation for the Phase 2/3 clinical trials, Incannex has undertaken a 12-week feasibility study whereby the trial design was provided to potential investigators along with a survey to gauge interest in conducting the study and identify any region-specific regulatory hurdles. This study involved contacting 195 sites across 14 countries in North American, Europe, South America, and Australasia. Sixty-three sites expressed interest in the conducting the study. Incannex anticipates that 20-30 sites will eventually be selected to conduct the clinical trials.

08:03 EST Federal Signal to acquire truck equipment manufacturer Blasters for $14M - Federal Signal signed a definitive agreement to acquire substantially all the assets and operations of Blasters, a manufacturer of truck-mounted waterblasting equipment, for an initial purchase price of $14M, subject to post-closing adjustments. In addition, there is a contingent earn-out payment of up to $8M. Based in Tampa, Florida, Blasters designs, manufactures and sells the Liquidator, an ultra-high pressure, water-based, road-marking and rubber-removal truck. Blasters also engages in the sale of certified pre-owned UHP waterblasting units and supports the aftermarket needs of its customers through parts and service offerings. The company anticipates completing the transaction over the next 90 days, subject to customary closing conditions.

07:46 EST Aerovate Therapeutics publishes results of Phase 1 study of AV-101 - Aerovate Therapeutics announced the publication of Phase 1 study results evaluating AV-101, a novel dry powder inhaled formulation of imatinib, in ERJ Open Research. The results showed that AV-101 was generally well tolerated and inhaled administration significantly reduced systemic exposure compared to orally dosed imatinib with no serious adverse events reported. AV-101 is being developed to address abnormal cellular proliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of pulmonary arterial hypertension. Imatinib is an anti-proliferative drug initially approved for the treatment of chronic myeloid leukemia. It has previously demonstrated a statistically significant and clinically meaningful benefit in PAH patients in the global Phase 3 IMPRES trial, conducted by Novartis, when administered orally as a tablet but was poorly tolerated due to adverse events. The development of imatinib for PAH was discontinued. Aerovate designed AV-101 to deliver imatinib throughout the airways to more directly access the diseased blood vessels in the lung, at or above concentrations observed with the oral dose while limiting systemic exposure. This allows for the potential to maximize efficacy while limiting the adverse events observed with oral imatinib. The Phase 1, placebo-controlled trial, with topline results previously reported at the American Thoracic Society 2022 International Conference, evaluated single and multiple ascending doses of AV-101, self-administered twice daily with an easy-to-use pocket-sized inhaler in 82 healthy adults. The single ascending dose portion of Aerovate's trial included 40 patients divided into 5 cohorts of 8 subjects each, who were administered a planned progression of 1 mg, 3 mg, 10 mg, 30 mg, and 90 mg single doses of inhaled AV-101 or placebo, compared to an additional cohort of 8 participants receiving 400 mg oral imatinib, the dose used in the IMPRES trial. The multiple ascending dose portion included 34 patients divided into 3 cohorts of up to 12 subjects each who received AV-101 or placebo at either 10 mg, 30 mg, or 90 mg twice daily for 7 days. At all doses, AV-101 demonstrated only moderate plasma accumulation and significantly lower systemic exposure compared to oral imatinib. No serious treatment-emergent adverse events were reported in either the SAD or the MAD cohorts. In the SAD portion of the trial, the most common TEAEs were dizziness and headache, whereas in the MAD portion of the trial, the most common TEAEs were short periods of cough and headache, primarily in the 90 mg cohort. Aerovate's Phase 2b/Phase 3 trial, called IMPAHCT, is underway to evaluate the safety and efficacy of inhaled AV-101 in adults with PAH. Enrollment is ongoing and topline data are expected from the Phase 2b portion of the trial in the fourth quarter of 2023 or first quarter of 2024.

07:45 EST Idaho Strategic sees 'significant opportunity' in U.S. domestic mining investing - Idaho Strategic Resources provides the following President's Letter to Stakeholders. "In times like these, there is a tendency both as an investor and employee of an operating company to place a disproportional level of importance on macro events, which can cause one to lose sight of the fact that the ensuing opportunities only prove valuable to the prepositioned companies that possess the ability to capitalize on the dislocations - and that we planned well ahead and sit exactly where we want to be. At this point in the United States' decarbonization and deglobalization plan, the market is beginning to sort out which companies possess those abilities - and which do not. And now more than ever I personally think it comes down to the people involved, their motives and established personnel, and their business and community track records. The goal with this President's Letter is not to discredit other projects and/or businesses, but more so to focus on the qualities of Idaho Strategic that will allow us to maximize the full value of the potential opportunities ahead, especially as the awareness of our industry widens amongst investors. It has become clear that the plan the U.S. Government has decided to take toward decarbonization and deglobalization is one that began with domestic end products, and then works its way upstream to domestic mineral processing and finally to domestic mining. In the U.S.' latest round of funding announced as part of the Inflation Reduction Act, approximately $2.8 billion dollars was distributed amongst many different battery minerals processing plants around the country. While this is a positive step in the right direction, the natural follow-on step is to invest in domestic sources and domestic mining to feed these newly funded processing plants. This is where I see a significant opportunity for our company and ultimately our stakeholders. Besides the fact that we control three of the top ten domestic rare earth elements properties and the number one thorium property in the country, as you well know we also own and operate the Golden Chest Mine and the New Jersey Mill. I know from speaking with many of our stakeholders that some place emphasis on the rare earth elements and thorium side of our business and some on the gold side of the business. But the truth is that I believe they are of equal importance. The rare earth elements and thorium side of our business serves as the nearly immeasurable blue-sky potential should our country follow through with its plans; while the gold production side of our business serves as our proof-of-concept that if/when we are successful defining mineable rare earth elements resource, we have the team and the knowledge that has already proven its ability to responsibly turn a resource into an operation, or to evaluate if another group possesses the necessary qualifications. There was a saying back in the day amongst old promotor types that you should "never ruin a good deposit by mining it". Over the many years of commodities cycles, I have witnessed numerous companies with great projects and plans that look good on paper, fail to ever produce an ounce of material simply because they are too focused on promotion and/or riding macro trends rather than doing the hard work. We are obviously not in that camp. Additionally, I can tell from our recent conversations with state and local governments, next generation energy companies, and potential investors that the characteristic which helps de-risk our business plan and our rare earth elements/thorium properties the most, is the fact that we have proven ourselves capable of mining at the Golden Chest Mine and processing at the award-winning New Jersey Mill. We have also realized our own form of ESG - that our personal stories matter... most of us at IDR grew up in and near the mining and timber industries of N. Idaho and experienced firsthand what it was like when an industry shuts down and the 'adults in the room' had not invested or planned for life after mining or logging, etc. for the younger folks in the community. This experience is in our DNA and a part of our journey that cannot be taught or replaced by consultants. While mining different commodities may have unique challenges, the team we have and our motivation as an operating company has proven invaluable regardless of the commodity we are extracting and overall business approach we advance. At Idaho Strategic, and as fellow shareholders, we have made a point that every dollar spent goes toward furthering our operations and creating value for all of us. The most obvious example of this is in our corporate compensation structure. Without divulging too much detail, I am not the highest paid employee in the company, that title is held by one of our mine engineers, however I am the largest stockholder of the company. I purchased my shares from a retiring founder and had to bet on myself to help build it. Out of our 55-employee base, the corporate office represents just 10% of our total annual salary expense, and our average corporate office employee makes around 70% of what our average underground miner makes. The reason our compensation structure is setup this way is because I have a philosophy that when times get tough, we should 'jump in the lifeboat together rather than reach for individual life jackets'. This is something I learned from experience more than once and an approach that has already proven itself as we grew the company from its modest beginnings. It is also a way to make sure everybody understands the vision and basis for our culture and that the only way we succeed, is together. In closing, as a country we have finally reached the point where those in charge see the err of their ways and are now telegraphing the willingness to look to domestic solutions and the ingenuity of the American spirit. In due time, we will quickly grow beyond the backward logic of funding processing facilities first because it's easy and signals forward motion to voters and begin to focus efforts on the supply constraints of mass electrification and the inevitability of increasing the output of our domestic mining industry. At IDR we have secured our seat-at-the-table by owning the land, not only in quantity but also in quality. Now we simply need to continue growing our relationships and increase our public visibility. We are having conversations with folks today that I never dreamed possible only a couple short years ago - it is an exciting time for sure."

07:39 EST Skeena Resources announces drilling results from Eskay Creek Project - Skeena Resources announced additional drilling results from the 21A West Zone delineation program as part of the recently completed 2022 regional and near mine exploration campaigns at the Eskay Creek gold-silver Project in the Golden Triangle of British Columbia. In an area previously modeled as barren waste rock, exploratory drill hole SK-22-1131 intersected high tenor gold and silver mineralization in Rhyolite facies rocks starting at 14 metres vertically below surface averaging 7.73 g/t Au, 16.8 g/t Ag over 17.20 m with notable high-grade subintervals including 9.47 g/t Au, 13.7 g/t Ag over 4.02 m and 14.61 g/t Au, 31.3 g/t Ag over 5.20 m. This drill hole is situated within the proposed open-pit and 35 metres along trend to the south of previously reported 2022 drill hole SK-22-1031, which intersected 2.21 g/t Au, 4.6 g/t Ag over 50.00 m. Additional near surface Rhyolite mineralization has also been encountered by the exploratory drill hole SK-22-1103, grading 3.08 g/t Au, 32.9 g/t Ag over 21.80 m and 4.52 g/t Au, 84.7 g/t Ag over 9.75 m, located within the proposed open-pit and 35 metres to the south of SK-22-1131. Due to a lack of historical drilling, this area of the 21A West Zone was considered barren waste rock for both the 2022 Resource Estimate and Feasibility Study. The recently discovered feeder-style mineralization that occurs within the Feasibility Study pit will be incorporated into the future resource and economic updates for Eskay Creek through incorporation of the 68,543 metres of exploration drilling completed since September 2021. As highlighted in the cross-section below, drill holes SK-22-1103, SK-22-1104 and SK-22-1131 have successfully contributed to the continued expansion and validation of the 21A West Zone discovered in late 2021. The 21A West Zone remains open for expansion both down-dip and along strike.

07:36 EST Revival Gold announces further results from Beartrack-Arnett Gold Project - Revival Gold announces further results from the Company's 2022 drilling program at the Beartrack-Arnett Gold Project located in Idaho, USA. "Today's results confirm the presence of high-grade gold mineralization in the South Pit area at Beartrack-Arnett. Similar grades are also present in the Joss area, which extends approximately 1.2 kilometers to the south. Together, the Joss and the South Pit areas encompass some two kilometers of favourable structure, and, in both areas, we see broad mineralized intersections and higher-grade zones. Mineralization is vertically dipping and conducive to open pit and underground mining", said Hugh Agro, President & CEO. "Data review is ongoing and follow-up drilling is being planned", added Agro.

07:35 EST First High-School Education receives delisting notice from NYSE - First High-School Education was notified by the NYSE that the staff of the NYSE Regulation has determined to commence proceedings to delist the ADSs, each representing three Class A Ordinary Shares of the company. Trading in the ADSs was suspended after the market close on the NYSE on November 7. The NYSE Regulation reached its decision to delist the ADSs because the company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15M. The company expects that the ADSs or the underlying Class A Ordinary Shares will be eligible to be quoted on an appropriate tier of the OTC Markets. To the extent the ADSs or the underlying Class A Ordinary Shares are quoted on the OTC Markets, the company expects that such markets may provide less liquidity than the NYSE and that the trading price of the securities may decline.

07:33 EST Dollar Tree announces four new leadership additions - Dollar Tree (DLTR) announced a number of key leadership additions, with Jennifer Bohaty, Terence Goods, Jennifer Silberman and Kristin Tetreault joining the organization as chief compliance officer, chief diversity officer, chief sustainability officer and chief communications officer respectively. Prior to joining Dollar Tree, Bohaty was global chief of ethics and compliance at LL Flooring. Goods most recently served as VP of diversity and inclusion at Southern Glazer's Wine and Spirits. Before Dollar Tree, Silberman was VP of ESG for Yeti (YETI). Tetreault joins Dollar Tree from Stanley Black & Decker (SWK).

07:32 EST Draganfly selected as preferred partner to DEF-C - Draganfly announces DEF-C, a Ukrainian company involved in the civil and defense sectors, has selected Draganfly as an exclusive provider of drones and related services. Draganfly will provide comprehensive equipment and solutions for emergency response, security, defense, and infrastructure, in addition to mapping, support, and public services. Draganfly's platforms can adapt to air and ground situations providing a range of solutions that solve integral issues. "The partnership between Draganfly and DEF-C will enable us to continue to provide equipment and solutions to the people of Ukraine," said Cameron Chell, President, and CEO of Draganfly. "The selection of Draganfly by DEF-C is a testament to the strength of our technology and our team's ability to provide turnkey solutions that meet the specific needs of our customer base."

07:30 EST BeiGene announces EC approval of Brukinsa - BeiGene announced that the European Commission, or EC, has approved Brukinsa for the treatment of adult patients with treatment-naive or relapsed/refractory CLL.

07:28 EST Marinus Pharmaceuticals appoints CEO Scott Braunstein as chairman - Marinus Pharmaceuticals announced that the board of directors has appointed CEO and board director, Scott Braunstein as chairman of the board. Braunstein succeeds Nicole Vitullo, who has retired from the board of directors following a 17-year tenure, including the past three years as chairwoman.

07:26 EST Globant acquires Australia's digital commerce consultancy eWave - Globant acquired eWave, an Australian-born digital commerce experience consultancy with expertise. With this acquisition, Globant expands into Australia and several Asian countries. Founded in 2009 in Australia, eWave operates in Europe and Asia with offices in Sydney, Melbourne, Hong Kong, Singapore, London, and Paris and centers of excellence in China, Eastern Europe & the Philippines. With over 200 collaborators, eWave implements end-to-end digital commerce transformations.

07:24 EST Wabtec to acquire Super Metal, terms undisclosed - Wabtec announced a definitive agreement to acquire Super Metal, a supplier of automated vehicles and equipment solutions that support rail operations. Super Metal is one of the leading Brazilian companies in the maintenance of way segment in the rail industry. This acquisition complements our Nordco acquisition and accelerates our strategy to expand into international markets. The financial terms of the acquisition were not disclosed.

07:22 EST Liberty Media to pursue split-off of Atlanta Braves to create new stock group - Liberty Media announced that its board of directors has authorized management to pursue a split-off (of the Atlanta Braves and its associated real estate development project and the creation of a new Liberty Live Group tracking stock. The Split-Off would be accomplished through the redemption of Liberty Media's existing Liberty Braves common stock in exchange for common stock of a newly formed company to be called Atlanta Braves Holdings. Atlanta Braves Holdings would hold all of the businesses, assets and liabilities currently attributed to the Braves Group, including Braves Holdings, LLC, which is the direct or indirect owner and operator of the Atlanta Braves Major League Baseball Club, certain assets and liabilities associated with the Atlanta Braves' stadium and mixed use development project, The Battery Atlanta, and corporate cash. In connection with the Split-Off, Liberty Media would redeem each outstanding share of its Series A, Series B and Series C Liberty Braves common stock for one share of the corresponding series of common stock of Atlanta Braves Holdings. As a result of the Split-Off, Liberty Media and Atlanta Braves Holdings would be separate publicly traded companies. It is expected that the intergroup interests in the Braves Group held by Liberty Media's existing Liberty SiriusXM Group and Formula One Group would be settled and extinguished in connection with the Split-Off in a manner to be determined. Following the completion of the Split-Off, Liberty Media would create a new third tracking stock group, the Liberty Live Group, through the reclassification of all of Liberty Media's remaining common stock, which includes the Liberty SiriusXM Group and the Formula One Group (the "Reclassification"). In connection with the Reclassification: Outstanding shares of Liberty Media's Series A, Series B and Series C Liberty SiriusXM common stock would be reclassified into shares of the corresponding series of both new Liberty SiriusXM tracking stock and Liberty Live tracking stock. Outstanding shares of Liberty Media's Series A, Series B and Series C Liberty Formula One common stock would be reclassified into shares of the corresponding series of both new Liberty Formula One tracking stock and Liberty Live tracking stock. The reclassification ratios for the creation of the new tracking stocks will be determined and announced at a later date. Liberty Media intends to attribute its businesses, assets and liabilities among the new tracking stock groups as outlined below: New Liberty SiriusXM Group - its interest in Sirius XM Holdings Inc., corporate cash, Liberty Media's 1.375% Cash Convertible Senior Notes due 2023 and related financial instruments, Liberty Media's 2.125% SiriusXM Exchangeable Senior Debentures due 2048, Liberty Media's 2.75% SiriusXM Exchangeable Senior Debentures due 2049 and margin loan obligations incurred by its wholly owned special purpose subsidiary, which are secured by shares of common stock of Sirius XM Holdings Inc., together with certain other assets and liabilities currently attributed to the Liberty SiriusXM Group. New Formula One Group - its interest in Formula 1, corporate cash, Liberty Media's 1% FWONK Cash Convertible Notes due 2023 and Liberty Media's 2.25% FWONK Convertible Senior Notes due 2027, together with certain other assets and liabilities currently attributed to the Formula One Group. Liberty Live Group - all of the businesses, assets and liabilities of Liberty Media other than those specifically attributed to the new Liberty SiriusXM Group or the new Formula One Group, including its interest in Live Nation Entertainment, Inc., corporate cash, certain public and private assets currently attributed to the Formula One Group, Liberty Media's 0.50% Live Nation Exchangeable Senior Debentures due 2050, margin loan obligations incurred by its wholly owned special purpose subsidiary, which are secured by shares of common stock of Live Nation Entertainment, Inc., together with other assets as may be determined from time to time by Liberty Media. Upon the effectiveness of the Reclassification, no group will initially have an intergroup interest in another group. Liberty Media expects its new Liberty SiriusXM common stock, new Liberty Formula One common stock and new Liberty Live common stock to trade on the Nasdaq Global Select Market or, if necessary, to be quoted on the OTC Markets. Additional information will be available at a later date. Liberty Media does not expect a change to the ticker symbols of its Liberty SiriusXM and Liberty Formula One common stock, and its new Series A, Series B and Series C Liberty Live common stock is expected to trade under the ticker symbols LLYVA, LLYVB and LLYVK, respectively. The Split-Off and the Reclassification will be subject to various conditions. Both transactions will be conditioned on, among other things, certain requisite approvals of the holders of Liberty Media's common stock and the receipt of opinions of tax counsel. In addition, the Split-Off will be conditioned on the requisite approval of Major League Baseball and the receipt of an IRS ruling. In addition, the Reclassification is dependent and conditioned on the approval and completion of the Split-Off, and will not be implemented unless the Split-Off is completed; however, the Split-Off is not dependent upon the approval of the Reclassification and may be implemented even if the Reclassification is not approved. Each of the Split-Off and the Reclassification is intended to be tax-free to stockholders of Liberty Media. Subject to the satisfaction of the conditions, Liberty Media expects to complete the Split-Off and the Reclassification in the first half of 2023.

07:20 EST Lucira Health announces national launch of Lucira connect test-to-treat service - Lucira Health (LHDX) announced the launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the $29 price of the test, excluding prescription costs. Lucira is also partnering with Pfizer (PFE) to increase awareness and education about the risks of COVID-19 and the availability of treatment options. "Rapid care from diagnosis to treatment is essential for managing you and your family's health and for reducing the spread of COVID-19," said Erik Engelson, President and CEO of Lucira Health. "Since our inception, we have been driven to revolutionize the testing industry by offering accurate and accessible healthcare from the comfort and safety of your home. The Lucira Connect program is one of the fastest and simplest ways to learn if you have COVID-19, understand what you can do about it, and to access appropriate treatment if prescribed by a medical professional. Through these partnerships, we aim to help simplify the way people access reliable information about their health and navigate COVID-19 infections to improve outcomes."

07:18 EST Bitfarms appoints Hofmeister to board of directors - Bitfarms appointed Edie Hofmeister to its board of directors, increasing the total number of board members to six. Most recently she served as Executive Vice President Corporate Affairs and General Counsel for Tahoe Resources where she led the Legal, Sustainability and Government Affairs departments and helped grow Tahoe from a junior exploration company to a mid-cap precious metals producer.

07:16 EST View Inc. launches View Partner Marketplace - View, Inc. announced the launch of the View Partner Marketplace, an app store now available to the customers of the company's recently launched Smart Building Cloud, the industry's first, complete cloud-native platform for smart buildings. The View Partner Marketplace enables View customers to deploy popular real estate applications, sensors, and software platforms with a single click, making it easier than ever for real estate owners and operators to quickly and securely digitize their real estate portfolios. The Smart Building Cloud provides real estate technology teams with all the software components required to connect, manage, and optimize a portfolio of smart buildings with strong cybersecurity protection and maximum flexibility. With the launch of the View Partner Marketplace, View is adding turnkey integrations with platforms and applications that make buildings healthier, more sustainable, more efficient, and easier to operate.

07:14 EST Xos signs dealership agreement with Foley Equipment Company - Xos announced it has signed a dealership agreement with Foley Equipment Company, a leading equipment dealer in the Midwest. Foley will sell Xos' flagship Class 5 and 6 stepvan, medium-duty Class 6 and 7 chassis cab MDXT, and heavy-duty Class 8 electric trailer HDXT, as well as provide service across Western Kansas. "We're thrilled to further expand our footprint in the Midwest with this dealership agreement with the industry-leading Foley team," said Jessica Savage, Head of Distribution at Xos. With Foley, the Xos dealership network now comprises five dealers across North America and over 50 dealership locations.

07:13 EST Katapult appoints Nancy Walsh as new CFO - Katapult (KPLT) has appointed Nancy Walsh as its new Chief Financial Officer, CFO, effective December 12, 2022. Former CFO Karissa Cupito is transitioning into a senior advisory role to support an orderly transition through the first quarter of 2023. Most recently, Cupito was Executive Vice President and Chief Financial Officer of LL Flooring Holdings (LL).

07:11 EST Invivyd announces partnership with Population Health Partners - Invivyd announced a partnership with Population Health Partners. Through the partnership, Invivyd will leverage PHP's best-in-class clinical development and regulatory expertise to help optimize Invivyd's product development programs. "This partnership is a reflection of our commitment to the rapid, capital efficient development of multiple candidates on an ongoing basis to match the pace of SARS-CoV-2 viral evolution and deliver timely, best-in-class antibody solutions for the prevention and treatment of serious diseases," said Invivyd CEO Dave Hering. "PHP has great experience in helping organizations like ours overcome the industry challenges inherent in navigating trials focused on large population medicine. This collaboration will add very specific skills and capabilities to our own in-house expertise and will bolster our organization. We are excited to work with PHP and its leadership team at this pivotal point in the evolution of our company."

07:09 EST New Jersey Resources reports Q4 EPS 50c, consensus 43c - Reports Q4 revenue $765.49M, consensus $428.91M. Steve Westhoven, president and CEO, stated, "Fiscal 2022 was an outstanding year for NJR. We took advantage of tightening energy markets across our complementary portfolio of businesses, allowing us to raise guidance two times during the fiscal year. We also made progress in executing our strategic growth objectives, highlighted by placing the Adelphia Gateway pipeline into service. This represented an important milestone for our company, and will help provide reliable energy to a capacity constrained region, which includes the Philadelphia metro area."

07:07 EST Evaxion Biotech's cancer candidate EVX-02 shows "promising" Phase 1/2a results - Evaxion Biotech announced "promising" clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. The company reported encouraging interim safety and immunogenicity data from the Phase 1/2a study of its personalized DNA-based immunotherapy, EVX-02. Treatment appeared to be well tolerated in all patients, with only very mild adverse events observed in relation to EVX-02 treatment. EVX-02 induced CD4+ and CD8+ specific T-cell responses in all patients, providing proof of mechanism for the company's DNA-delivery technology, in that the delivered EVX-02-DNA gave rise to immune reactions to its encoded neoantigen peptides. T-cell responses were robust and long-lasting. A full clinical trial report for the EVX-02 Phase 1 study is expected in 2Q23.

07:04 EST Target announces largest Black Friday week sale ever from Nov. 20-26 - Target announced its largest Black Friday week sale ever from Nov. 20-26, online and in stores, to help guests prepare for the holidays. The top deals include some of the retailer's best planned prices of the season - up to 50% off electronics, toys and video games, kitchen appliances, new and trending gifts, everyday essentials and more. The savings will continue Nov. 27-28 with a two-day Cyber event featuring hundreds of thousands more deals exclusively on Target.com and the Target app.

07:03 EST Regeneron, CytomX Therapeutics announce research collaboration - Regeneron Pharmaceuticals (REGN) and CytomX Therapeutics (CTMX) announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform. The collaboration is strategically focused on applying CytomX's biologic masking strategies to develop investigational Regeneron bispecifics that remain inactive until activated by proteases in the tumor microenvironment. This technology has the potential to widen the therapeutic window and help minimize off-target effects for these next-generation T-cell engaging therapies, potentially addressing tumor types that have historically been unresponsive to immunotherapy. Under the agreement, Regeneron and CytomX will collaborate on the discovery activities to identify and validate conditionally active bispecific antibodies. Regeneron will be responsible for funding preclinical and clinical development and commercialization activities. CytomX will receive an upfront payment of $30M and will be eligible to receive future target nomination payments and preclinical, clinical, and commercial milestones of up to $2B. CytomX is also eligible to receive tiered global net sales royalties.

06:58 EST Macy's reports Q3 gross margin 38.7%, down from 41% a year ago - Merchandise margin decline was driven by a year-over-year increase in promotional and permanent markdowns within the Macy's brand, as the company sold through slower moving categories including casual apparel, soft home, and warmer weather seasonal goods. Delivery expense as a percent of net sales was relatively consistent with the prior year. Higher fuel costs more than offset the impact of a 2-percentage point decline in digital penetration and reductions in cost-per-package.

06:56 EST EU passenger car registrations up 12.2% in October - In October, new passenger car registrations continued their upward trend, rising 12.2% in the European Union, with 745,855 units sold, said the European Automobile Manufacturers Association. "However, this result remained nearly 290,000 units below the October 2019 pre-pandemic levels," the group stated. Ten months into 2022, EU new car registrations remained in negative territory by 8.1%, as recent improvements were not enough to offset losses cumulated from January to July this year, the group added. Publicly traded automakers include Ford (F), General Motors (GM), Honda (HMC), Mercedes-Benz Group (DDAIF), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY).

06:47 EST Iron Mountain expands footprint in North America - Iron Mountain has expanded their North American data center footprint with the purchase of a 10 acre land parcel and 50+ MVA (expandable to 100+ MVA) substation in Phoenix, Arizona to develop a 36 megawatt, 230K square foot data center (AZP3). The land is adjacent to Iron Mountain's existing 39-acre campus that houses their AZP1 (41 megawatt) and AZP2 (48 megawatt) data centers. Phase one of the AZP3 expansion is expected to be delivered in 2024.

06:40 EST Alibaba raises share repurchase authorization by $15B - "We generated another quarter of healthy revenue growth of 3% year-over-year in spite of the impact on consumption demand by the COVID-19 resurgence in China as well as slowing cross border commerce due to increasing logistics costs and foreign currency volatility," said Toby Xu, CFO of Alibaba Group. "We have continued to take a holistic approach to improve operating efficiency and cost optimization throughout the company that resulted in adjusted EBITA growth of 29% year-over-year. With strong net cash position and cash flow generation, as of November 16, 2022, we had repurchased approximately $18 billion of our shares under our existing $25 billion share repurchase program. In addition, our board has approved to upsize the share repurchase program by another $15 billion and extend the program to the end of fiscal year 2025."

06:32 EST Immunic reports new data from EMPhASIS trial of vidofludimus calcium - Immunic reported newly available data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium, in relapsing-remitting multiple sclerosis, or RRMS. Long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time, and compares favorably to historical trial data for currently available multiple sclerosis, or MS, medications. EMPhASIS is an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group trial, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS. The trial included a 24-week blinded main treatment period testing 10, 30 and 45 mg of vidofludimus calcium and placebo. In the third quarter of 2020, Immunic reported that the trial achieved both primary and key secondary endpoints with high statistical significance, with a safety and tolerability profile similar to placebo. The trial also includes an optional long-term open-label extension, or OLE, phase running up to 9.5 years. An interim analysis was performed with data extraction in October, when 209 patients remained on treatment in the OLE phase, some of whom have already received more than 180 continuous weeks of active treatment with vidofludimus calcium. During the 24-week double-blind main treatment period, 12-week and 24-week Confirmed Disability Worsening events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. In the OLE phase, the proportion of patients free from 12wCDW was 97.6% after 48 weeks and 94.5% after 96 weeks of vidofludimus calcium treatment as compared to the start of the OLE phase. Similar results were observed for 24wCDW and sustained CDW. The OLE phase also showed low relapse activity.

06:31 EST Babcock & Wilcox awarded $24M contract for North American oil refinery - Babcock & Wilcox's B&W Thermal and B&W Environmental business segments have been awarded a contract for more than $24M to supply two industrial package boilers, auxiliary equipment and advanced emissions control technologies for a petroleum refinery in North America. B&W Thermal will design and supply two package boilers, burners, economizers and other equipment for the project. B&W Environmental also will supply two select catalytic reduction systems to control nitrogen oxide emissions.

06:09 EST Air Products, Mabanaft to build green energy import terminal in Germany - Air Products and Mabanaft, through its subsidiary Oiltanking Deutschland, announced their intention to build Germany's first large-scale, green energy import terminal in the Port of Hamburg. This joint development agreement is an important step towards the development of a green ammonia import and distribution infrastructure in the Port of Hamburg. The project was announced at a ceremony in Hamburg, which was supported by German Federal Minister for Economic Affairs and Climate Action Robert Habeck and First Mayor of Hamburg Dr. Peter Tschentscher. Targeted to provide hydrogen to Germany in 2026, the planned import terminal is to be located at Mabanaft's existing tank terminal in the port. This location offers strategic access to green ammonia from large-scale green hydrogen production facilities operated by Air Products and its partners around the world. The intention is to convert the ammonia to green hydrogen via Air Products' facilities in Hamburg, before distributing it to buyers locally and across northern Germany. This plan responds to the accelerating demand for clean energy to meet climate objectives and the need to diversify energy sources.

06:03 EST KBR joint venture awarded optimization stage engineering services contract - KBR announced that BP Exploration has awarded an optimization stage engineering services contract to SOCAR-KBR for the Shah Deniz compression project in the Azerbaijan sector of the Caspian Sea. The project is in early pre-FID stage. SOCAR-KBR is a joint venture of Azerbaijan's state oil company, SOCAR, and KBR. The Shah Deniz compression platform project will be the first in the Caspian region to feature crewless operations, delivering process optimization through cutting-edge, high-end technology. Under the contract, SOCAR-KBR will support optimization and provide class-3 engineering services. Scope also includes engineering to enable integration of the new platform to the existing system and provide shore power to reduce the carbon footprint in support of BP's net-zero targets. KBR recently completed the initial assessment for the flagship project using their proprietary KMIT to provide detailed estimates of timing and resourcing of maintenance.

05:52 EST NetEase anticipates licenses covering several Blizzard titles will expire - NetEase announced that it anticipates that its licenses covering the publication of several titles of Blizzard Entertainment in China will expire in accordance with their terms on January 23, 2023 and will not be renewed. The affected games are World of Warcraft, the StarCraft series, Hearthstone, Heroes of the Storm, Overwatch and Diablo III. The net revenues and net income contribution from these licensed Blizzard games represented low single digits as a percentage of NetEase's total net revenues and net income in 2021 and in the first nine months of 2022. The expiration of such licenses will have no material impact on NetEase's financial results. The co-development and publishing of Diablo Immortal is covered by a separate long-term agreement and will continue.

05:43 EST Elbit Systems awarded $200M supply contract - Elbit Systems announced that it was awarded a contract valued at approximately $200M to supply Electronic Warfare and airborne laser technologies to protect military helicopters of a country in Asia-Pacific. The contract will be executed over a four-year period. Under the contract, Elbit Systems will supply self-protection suites comprised of the Infra-Red Passive Airborne Warning Systems and the Mini-MUSIC Direct Infra-Red Counter Measure Systems. These protection suites are designed to increase survivability and mission effectiveness of helicopters in arenas threatened by shoulder-fired heat seeking anti-aircraft missiles. The protection suites to be supplied will be installed aboard both attack and utility helicopters. MUSIC DIRCM systems have been selected to-date by numerous customers across the globe.

05:36 EST Stellantis to acquire aiMotive, terms undisclosed - Stellantis and aiMotive, a developer of advanced artificial intelligence and autonomous driving software, announced that they have entered into an agreement for Stellantis to acquire aiMotive. Stellantis' software teams are already developing the three all-new technology platforms that will be deployed at scale across the four all-new STLA vehicle platforms, starting in 2024. The software strategy, as announced during Stellantis' Software Day in December 2021, is expected to generate approximately EUR 20B in incremental annual revenues by the end of the decade, as part of the Dare Forward 2030 strategic plan bold objectives, backed by more than a EUR 30B investment in electrification and software. aiMotive is based in Budapest, Hungary, with offices in Germany, the United States and Japan, with over 200 employees worldwide, including engineers with advanced artificial intelligence and autonomous driving expertise. aiMotive will operate as a subsidiary of Stellantis, maintaining its operational independence and startup culture. Founder Laszlo Kishonti will remain as CEO. It will continue selling three areas of its current technology product portfolio, including aiData, aiSim and aiWare, to other partners. Stellantis will establish a board of directors to oversee aiMotive while preserving its startup mindset of rapid innovation. aiMotive team will be fully part of the Stellantis autonomous driving and artificial intelligence teams.

05:21 EST Willis Towers Watson announces new collaboration with Liberty Specialty Markets - WTW has announced a new collaboration with insurers Liberty Specialty Markets, or LSM, and Markel, launching the pilot phase of a digital commercial insurance platform. Digital connectivity and trading of commercial risks between all stakeholders is increasingly recognized by the market as essential to modernize the insurance value chain, maintain competitiveness, drive better client solutions and ultimately sustain the relevance of the insurance industry. But inflexible legacy systems and incompatible digital practices can often lead to fragmented end-to-end operations.

05:07 EST Wells Fargo, HSBC expand DLT solution to include offshore yuan - Wells Fargo (WFC) and HSBC (HSBC) announced that the blockchain-based solution they are using for bilateral FX settlements is expanding to include the offshore yuan. The offshore yuan marks the fifth currency to be settled between the two banks using a shared settlement ledger that currently encompasses the U.S. dollar, Canadian dollar, British pound sterling, and the euro. Since launching the shared DLT solution in December 2021, HSBC and Wells Fargo have settled over $200B in transactions and plan to add additional currencies over the coming months.